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Cardiac resynchronization 
therapy: a comparison among left 
ventricular bipolar, quadripolar and 
active fixation leads
M. Ziacchi1, I. Diemberger  1, A. Corzani1, C. Martignani1, A. Mazzotti1, G. Massaro1, 
C. Valzania1, C. Rapezzi1, G. Boriani1,2 & M. Biffi1
We evaluated the performance of 3 different left ventricular leads (LV) for resynchronization therapy: 
bipolar (BL), quadripolar (QL) and active fixation leads (AFL). We enrolled 290 consecutive CRTD 
candidates implanted with BL (n = 136) or QL (n = 97) or AFL (n = 57). Over a minimum 10 months 
follow-up, we assessed: (a) composite technical endpoint (TE) (phrenic nerve stimulation at 8 V@0.4 ms, 
safety margin between myocardial and phrenic threshold <2V, LV dislodgement and failure to achieve 
the target pacing site), (b) composite clinical endpoint (CE) (death, hospitalization for heart failure, 
heart transplantation, lead extraction for infection), (c) reverse remodeling (RR) (reduction of end 
systolic volume >15%). Baseline characteristics of the 3 groups were similar. At follow-up the incidence 
of TE was 36.3%, 14.3% and 19.9% in BL, AFL and QL, respectively (p < 0.01). Moreover, the incidence 
of RR was 56%, 64% and 68% in BL, AFL and QL respectively (p = 0.02). There were no significant 
differences in CE (p = 0.380). On a multivariable analysis, “non-BL leads” was the single predictor of 
an improved clinical outcome. QL and AFL are superior to conventional BL by enhancing pacing of the 
target site: AFL through prevention of lead dislodgement while QL through improved management of 
phrenic nerve stimulation.
Cardiac resynchronization (CRT) is a proven heart failure therapy, but a minority of patients (pts) have no clinical 
benefit1. The lack of improvement is multi-faceted, owing both to pts selection and technical CRT issues. Phrenic 
nerve stimulation (PNS), high myocardial threshold (HMT), left ventricular lead dislodgement (LD) and failure 
to achieve the target pacing site are the most frequent technical issues1,2, that were aimed at by the introduction of 
new left ventricular leads such as the quadripolar (QL) and the bipolar active fixation leads (AFL)3–6. This is the 
first study comparing 3 different LV lead platforms for CRT with defibrillator: bipolar passive fixation lead (BL), 
QL and AFL. The purpose was to evaluate at long term the performance of these 3 different LV leads from both 
the technical and clinical outcome standpoint.
Methods
This was a single center observational study carried out on pts consecutively implanted with a CRT with defi-
brillator (D) and 3 different LV lead platforms: BL, QL and AFL. The study of LV performance was approved by 
the local Ethic Committee of the University Hospital S.Orsola-Malpighi (Bologna, Italy) and complies with the 
principles outlined in the Declaration of Helsinki. Pts provided informed consent for data collection and analysis. 
All the 4 implanting physicians have ≥10 years experience in CRT implantation, hence a learning-curve effect 
was excluded. The study enrolled all the pts implanted with CRT-D from January 2012 to June 2015. Pts with 
life expectancy <12 months were excluded. BL were implanted from January 2012 to December 2013; QL from 
June 2012 to June 2015, bipolar AFL were implanted from September 2013 to June 2015 (when they became 
available). Since December 2013 onward any bipolar lead implanted was an AFL. During the implant procedure 
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an angiogram (obtained with an occlusive catheter) was taken in 45° left anterior oblique view (LAO) and in 
30° right anterior oblique view (RAO). The target pacing site (TPS) was defined as the site with the longer Q-LV 
among all accessible veins7 sized at least 5 F. Preoperative imaging helped the selection process: areas of scarred 
tissue as detected by history of previous MI, echocardiography, SPECT, MR scan, were avoided to ensure stimu-
lation of viable LV tissue, that predisposes to CRT non-response8. Q-LV was firstly measured at the great cardiac 
vein placement, then in the other coronary veins that had a minimum 5 F diameter (as showed by the angiogram), 
starting from the easiest accessible and ending with the more challenging one. Only coronary veins having a ratio 
Q-LV/total QRS duration ≥0.7 were considered suitable for the TPS. Thus, a TPS was achieved when this ratio 
was obtained by any available LV electrode7. When it became available, an AFL was preferred in the presence of a 
suitable coronary vein leading to posterior or lateral or antero-lateral site whose length was not exceeding 4 cm, 
whereas a QL was chosen for longer veins. LV leads location is shown in Fig. 1. Pacing configuration (LV-only vs 
Biventricular), atrioventricular and interventricular delay optimization occurred before discharge in all patients. 
“LV only” pacing configuration means LV stimulation avoiding right ventricle stimulation in the event of a nor-
mal intrinsic PR interval. The atrioventricular and interventricular optimization was guided by ECHO with the 
iterative method.
LV myocardial threshold, pacing impedance and phrenic nerve threshold were evaluated before discharge 
and at follow-up (in all pacing vector configurations). All the pts were evaluated clinically before implantation, at 
hospital discharge, and after at least 10 months of continuous resynchronization therapy.
We assessed composite technical endpoint (TE), clinical endpoint (CE), and LV reverse remodeling (RR) by 
Echocardiography.
Definition of the composite TE. PNS at 8 V@0.4 ms in at least one pacing configuration (all the program-
mable LV pacing configuration were tested); safety margin between myocardial and phrenic threshold <2 V in 
the chosen pacing configuration not correctable with pacing vector reprogramming; left ventricular lead dis-
lodgement requiring a re-operation and correctable with pacing vector reprogramming (variation of myocar-
dial threshold >1.5 V suggested a possible LV lead dislodgement that need to be confirmed with an X-ray in 
antero-postero and latero-lateral view); failure to achieve the TPS.
Figure 1. Final tip (A) and catode (B) locations of LV leads.
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Definition of composite CE. death for any cause, hospitalization for heart failure and heart transplantation 
after at least 10 months of resynchronization therapy; infection leading to lead extraction.
RR (reduction of end systolic volume >15% compared to the value before the implant) was evaluated by the 
echocardiography according to Ypenburg classification9 after 10 months of continuous CRT (percentage of pacing 
>99%). The reproducibility of measurements in our center has been previously reported10.
Statistical Analysis
Descriptive statistics are reported as mean ± standard deviation (SD) for normally distributed 
variables. Categorical variables are reported as percentages and were statistically tested by means of the χ2. 
Freedom from clinical and technical endpoints was studied by means of the Kaplan–Meier method. Univariate 
Cox proportional hazards models were used to investigate the predictors of clinical outcome. Variables that 
showed an effect on the clinical outcome with a significance level <0.2 in the univariate analysis were entered into 
the multivariate Cox proportional hazards models. Cox model findings are presented as hazard ratios (HRs) and 
95% confidence intervals (CIs). A two-tailed p-value of <0.05 was considered statistically significant.SAS 9.3, SAS 
Institute Inc., Cary, NC, USA was used for statistical analysis.
Results
Population. Table 1 reports clinical characteristics according to the implanted lead. BL group had a slightly 
lower EF owing to implantation before the 2013 guidelines11 release (NYHA 3–4 patients more represented), 
whereas the AFL patients were on average older, with higher prevalence of old females, AF, diuretic use and 
comorbidities. All the patients were on optimized medical therapy for heart failure therapy. The leads used in the 
study period are reported in Table 2. During follow up, CRT delivery was not significantly different across the 
groups, 97.8% (BL) vs 99% (QL) vs 100% (AFL).
Technical composite endpoint. The incidence of composite technical endpoint at long term follow up is 
reported in Table 3 and Fig. 2; overall TE occurred in 27.5%, but did not prevent CRT delivery in any patient dur-
ing follow-up. Dislodgment requiring re-operation occurred in 10 (7.4%) BL patients, in 4 (4.1%) QL patients (2 
with a Quartet St. Jude Medical leads and 2 with Performa Medtronic leads), and in no AFL patient. Five of these 
patients (4 with a BL and 1 with a QL) could no longer be paced in the same targeted site because of coronary vein 
occlusion (after the LV lead dislodgement).
Significant differences in the composite TE were observed amongst the 3 LV lead groups: QL enabled supe-
rior management of PN, whereas AFL proved superior for LV targeting and prevention of dislodgment (Table 3, 
Fig. 2) regardless of a difficult coronary vein anatomy and right atrial enlargement (Fig. 3).
Composite clinical endpoint. The incidence of composite clinical endpoint at 12 months follow up was 
10.3% without significant differences between the 3 groups (p = 0.38) (Table 3, Fig. 4). Infections leading to 
All Bipolar leads Quadripolar leads Active fixation leads P*
N 290 136 97 57
Male (n.%) 213 (73.4) 102 (75.0%) 76 (78.4%) 35 (61.4%) 0.16
Mean Age (yrs) 66.3 ± 12.6 63.9 ± 12 67.1 ± 12.2 70.7 ± 13.5 0.08
Ischemic etiology (n,%) 94 (32.4) 45 (33.1%) 32 (33.0%) 17 (29.8%) 0.28
NYHA I-II (n,%) 93 (32.1) 37 (27.2%) 36 (37.1%) 18 (31.6%) 0.19
NYHA III.IV (n,%) 197 (67.9) 99 (72.8%) 61 (62.9%) 39 (68.4%) 0.12
Mean QRS width (ms) 161.8 ± 25.1 161.0 ± 25.5 161.6 ± 23.9 164.1 ± 26.5 0.54
LBBB (n,%) 237 (81.7) 198 (80.1%) 78 (80.4%) 50 (87.7%) 0.81
Permanent AF (n,%) 59 (20.3) 27 (19.9%) 18 (18.6%) 14 (24.6%) 0.77
Mean LV EDV (ml) 226.5 ± 71.5 242.4 ± 75 213.7 ± 64.3 208.6 ± 67.0 0.07
Mean LV ESV (ml) 168.1 ± 59.7 183.0 ± 61.8 156.5 ± 53.5 150.5 ± 56.9 0.08
Mean LV EF (%) 26.0 ± 5.6 24.1 ± 5.2 27.9 ± 5.4 27.8 ± 5.2 0.07
Severe kidney disease (n,%) 24 (8.3) 8 (5.9) 9 (9.3) 7 (12.3) 0.31
Hypertension (n,%) 165 (56.9) 65 (47.8) 61 (62.9) 39 (68.4) 0.01
Hypercolesterolemia (n,%) 142 (49) 57 (41.9) 49 (50.5) 36 (63.2) 0.02
Smoke (n,%) 70 (24.1) 33 (24.2) 27 (27.8) 10 (17.5) <0.001
Diabetes (n,%) 71 (24.2) 31 (22.3) 27 (27.8) 13 (22.8) 0.64
Beta-Blockers (n,%) 261 (90.0%) 124 (91.2%) 87 (89.7%) 50 (87.8%) 0.83
ACE-I/ARB (n,%) 238 (82.1%) 114 (83.8%) 80 (82.5%) 44 (77.2%) 0.91
Diuretics (n,%) 263 (90.7%) 121 (89.0%) 88 (90.7%) 54 (94.7%) 0.90
Potassium-sparing (n,%) 168 (57.9%) 75 (55.1%) 57 (58.8%) 36 (63.2%) 0.51
Average Follow up (months) 12 12 12.1 10.4 0.91
Table 1. Study population. *Chi square test performed. Legend: LBBB: left bundle branch block; AF: atrial 
fibrillation; LV: left ventricular; EDV: end diastolic volume; ESV: end systolic volume; EF: ejection fraction.
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system removal occurred in 2 pts (one in BL group and the other in the QL group) after respectively 8 and 6 
months from implantation (Table 3).
Reverse remodeling. At follow up 170/270 (63%) living patients had reverse remodeling (reduction of 
ESV > 15%), but there were differences in the 3 LV lead groups (Fig. 5): responders were 56%, 68%, 64% respec-
tively in BL, QL and AFL (p = 0.02). No significant differences occurred between QL and AFL. On a multivariable 
regression analysis, only “non-BL leads” were associated to an improved clinical outcome (reverse remode-
ling + free from heart failure related hospitalizations/death/heart transplantation; see Table 4).
Figure 2. Composite technical endpoint with different left ventricular leads.
Left ventricular leads Manufacturer Model N (%)
Bipolar
Boston Scientific Easy Track 3 4548 41 (14)
Medtronic Ability 4296,4196 66 (23)
St. Jude Medical Quicksite 1056T 29 (10)
Quadripolar
Boston Scientific Acuity X4 4677 1 (0.3)
Medtronic Performa 4298 72 (25)
St. Jude Medical Quartet 1458Q 24 (8)
Active fixation Medtronic Stability 20066 57 (20)
Table 2. LV leads employed in the study population.
All Bipolar leads Quadripolar leads Active fixation leads P*
Technical Endpoints
PNS > 8 V @ 0.4 ms (n,%) 33 (11) 23 (17) 8 (8) 2 (4) 0.014
Safety Margin between PN and LVT 
threshold <2 V (n,%) 24 (8) 19 (14) 2 (2) 3 (5) 0.003
Failure to achieve TPS (n,%) 26 (9) 22 (16) 3 (3) 1 (2) <0.001
LV Lead dislodgment (n,%) 27 (9) 21 (15) 5 (5) 0(0) 0.003
LV Lead dislodgement requiring a 
re-operation 14 (4.8) 10 (7.4) 4 (4.1) 0(0) 0.005
Clinical Endpoints
Death for any causes (n,%) 18 (6.2) 10 (7.3) 5 (5.2) 3 (5.3) 0.75
Hospitalization for heart failure (n,%) 26 (9) 17 (12.5) 7 (7.2) 2 (3.5) 0.24
Heart Transplantation (n,%) 3 (1) 2 (1.5) 1 (1) 0 0.65
Infection leading to lead extraction 2 (0.7) 1 (0.7) 1 (1) 0 0.84
Table 3. Technical and Clinical Endpoints. *Chi square test performed. Legend: PNS: phrenic nerve 
stimulation; LVT: left ventricular threshold; TPS: target pacing site; LV: left ventricular.
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Discussion
This is an observational cohort, not a randomized clinical trial with the inherent limitation (as described in the 
dedicated section) but representing the real world. Our study highlights that QL and mostly AFL enable an easier 
targeted LV lead placement compared to traditional BL, with a trend in favor to less heart failure-related hospital-
izations. Owing to superior stability coupled with small size, trackability along tortuous veins and steroid elution 
on either tip or ring electrode, the Attain StabilityTM proved superior in overcoming the main challenges to LV 
lead implantation at a targeted placement site regardless of coronary vein anatomy and risk of dislodgement. In 
fact, short and thin veins as long as 3 cm could be considered for LV lead stimulation (Figs 1 and 3). Targeted LV 
stimulation has indeed demonstrated to increase the chances of RR and clinical improvement following CRT 
implantation12.
Figure 3. Coronary sinus angiogram and target pacing site evaluation. Panel A: coronary sinus angiogram 
that showed a lateral short vein; panel B: Q-LV methods for the electrical delay evaluation9; panel C: final left 
ventricular lead position in right anterior oblique (RAO) view; panel D: final left ventricular lead position in left 
anterior oblique (LAO) view.
Figure 4. Hospitalization for heart failure with different left ventricular leads.
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Technical Endpoint and LV leads. PN, LV lead dislodgement and high LVT prevent a stable and targeted 
CRT delivery along follow up, thus creating the background for CRT-nonresponse2–6,13,14. New multipolar leads 
enable an easier management of PN and broader possibilities to reach the target stimulation site. Despite this, 
the LVT threshold at the target location may not differ from one lead platform to the other, being dependent on 
local tissue properties, electrode technology, and stabilization strategy2–6,13,15. Whereas QL leads ensure an easier 
management of PN and fewer lead dislodgments compared to conventional BL leads in comparative studies16, the 
dislodgement rate of QL was 3.5% at 3 months in Tomassoni multicenter study5, and very similar at one year in 
this study (with some differences across manufacturers). Enhanced stability portends improved clinical outcome: 
Forleo et al.16 observed a reduction of heart failure-related hospitalizations and of LV lead dislodgements by QL 
compared to conventional BL, although the study was not randomized and no strategy for coronary vein selection 
was used for both type of leads. Being RR data not reported in that study16, it is likely that the clinical outcome 
has been influenced also by factors other than the QL technology, that is the TE may not be related to the CE. In 
our study, the strategy aimed at the latest activated site of the accessible veins at least 5 F in size in all the patients, 
CRT delivery was optimized and delivered at the same extent in all the patients, hence the incidence of TE, the RR 
extent and the CE can be associated to lead technology.
Figure 5. Reverse remodeling and quality of response11 by 10-months Echocardiography.
Variables
Odds Ratio (Low 95% CI-
High 95% CI) P value
Univariate analysis
Age 1.00 (0.98–1.02) 0.735
Male 1.09 (0.65–1.84) 0.743
Non ischemic Etiology 1.43 (0.87–2.35) 0.155
Diabetes 0.91 (0.53–1.56) 0.732
Kidney disease (VFG < 30 ml/
min) 0.58 (0.25–1.38) 0.218
LBBB 1.59 (0.87–2.93) 0.135
150 < QRS < 170 1.05 (0.65–1.71) 0.835
QRS > 170 0.99 (0.60–1.62) 0.962
Baseline EF < 20% 0.65 (0.31–1.37) 0.260
ESV/BSA < 43 ml/m2* 2.74 (0.54–13.81) 0.223
Achieving TPS 1.66 (0.73–3.80) 0.228
Non bipolar lead 2.02 (1.26–3.22) 0.003
Multivariate analysis**
Male 1.31 (0.76–2.27) 0.333
Non ischemic Etiology 1.56 (0.93–2.62) 0.089
LBBB 1.71 (0.91–3.22) 0.095
Non bipolar lead 1.99 (1.24–3.20) 0.004
Table 4. Reverse Remodeling + free from HF related hospitalizations/death/heart transplantation. *BSA 
calculated with Mosteller’s Formula √[(height*weight/3600)]. **Only parameters with a p value < 0.200 and 
demographic characteristics where included in the multivariate analysis. Legend: LBBB: left bundle branch 
block; ESV: end systolic volume; BSA:body surface area; TPS: target pacing site.
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Clinical Endpoint. Resynchronization therapy is a customized therapy, targeted pacing site being a key point 
for LV reverse remodeling and long-term outcome12. LV lead placement at a scar-free site8,17 possibly mechani-
cally12 or electrically delayed (Fig. 3 panel B) improve RR up to 70% of patients. Avoidance of LV dislodgement 
over the first year after implantation is hence of pivotal importance, since displacement has been reported to 
reach a ceiling after 10 months11,14,15. Under this perspective, the use of AFL enhances the capability of targeted 
LV lead placement4 while ensuring stability over the long term (Table 3), possibly improving the clinical outcome 
(Table 3). This is particularly important as only 35% of patients have more than a single coronary vein suitable 
to LV lead placement6, and QL leads may not be successfully implanted in up to 7% of patients17,18. Despite these 
considerations in our study the “novel technologies”, while significantly increasing RR, failed to show an improve-
ment in clinical composite score. The reason for this result presumably lay in study design which compared three 
active strategies for CRT (and not a placebo/drug-only arm) that may require longer follow-up time to show 
superiority in terms of survival/hospitalization. However, in view of the close relationship between RR and clin-
ical outcomes we believe that future studies with larger cohorts and longer follow-up will obtain positive results 
also in terms of hospitalization reduction and even survival. One possible limitation of bipolar AFL could be the 
impossibility to elicit multi-point LV stimulation at inter-electrode intervals broader than 20 mm; this novel tech-
nology awaits to prove superiority in non-responders to single site LV stimulation in the randomized More-CRT 
MPP study (Clinical Trials.gov Identifier NCT02006069), and has been shown to have a highly individual efficacy 
on acute hemodynamic measurements, when a strictly pathophysiologic approach is applied19. Some concern 
could be raised about AFL extractability in the event of CIED infection: the conception of the Attain StabilityTM 
lead is such to minimize the labor of lead extraction, and although leads being in place for several years have to be 
challenged, we previously reported an uneventful extraction procedure in a patient (not included in this popula-
tion being a CRTP recipient) with a device infection implanted with an AFL lead20.
Limitations
This is a single center, retrospective non-randomized study that reflects the clinical practice in CRT at an experi-
enced teaching hospital in consecutively implanted patients. The population is outnumbered for mortality end-
points, and a longer follow up could strengthen our argumentation. Moreover, the potential confounders in the 
assessment of CE were even among the study groups owing to a similar care in device tailoring and CRT delivery 
along follow up. Finally we must remember that measuring RR with echocardiography is challenging and shows 
important inter-observer variability even if our inter-observer variability is quite good10.
Conclusions
Left ventricular QL and AFL enable a superior RR compared to conventional BL, owing to a decreased dislodge-
ment rate from the targeted stimulation site and freedom from other technical challenges21. AFL and QL solve the 
same technical issues, but in different way, the first one with the active fixation and the second one with electronic 
repositioning. Both new technologies permit a targeted pacing, then AFL is the best lead to prevent dislodgement 
instead QL is the best for the PN management.
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